Učitavanje...
Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
Purpose: There is limited standard treatment for patients with advanced cholangiocarcinoma after refractory of chemotherapy. Apatinib is a tyrosine kinase inhibitor targeting VEGFR-2, which exhibited broad-spectrum antitumor activities in previous studies. We aim to evaluate the efficacy and safety...
Spremljeno u:
| Izdano u: | J Cancer |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Ivyspring International Publisher
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7847639/ https://ncbi.nlm.nih.gov/pubmed/33532001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.53482 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|